马铃薯疮痂病(potato common scab)是由链霉菌(Streptomyces spp.)引起的土传兼种传细菌性病害,给马铃薯产业带来巨大的经济损失。为了筛选出防治马铃薯疮痂病的菌药组合,本研究将5株芽孢杆菌复配,筛选出对3种疮痂链霉菌的最优拮抗菌株...马铃薯疮痂病(potato common scab)是由链霉菌(Streptomyces spp.)引起的土传兼种传细菌性病害,给马铃薯产业带来巨大的经济损失。为了筛选出防治马铃薯疮痂病的菌药组合,本研究将5株芽孢杆菌复配,筛选出对3种疮痂链霉菌的最优拮抗菌株组合BEV2+FM2-4,并通过萝卜幼苗试验验证了其对普通疮痂链霉菌(S. scabies)SCA3有明显的拮抗作用。采用平板菌落计数法测定了3种化学药剂(2.5%咯菌腈悬浮种衣剂(FS)、50%氟啶胺悬浮剂(SC)和20%溴硝醇可溶液剂(SL))对疮痂链霉菌的抑制作用,结果表明,50%氟啶胺SC对疮痂链霉菌的抑制效果最好,其EC_(50)值为0.442μg/mL;其次是20%溴硝醇SL,EC_(50)值为0.536μg/mL;2.5%咯菌腈FS的EC_(50)值为2.916μg/mL。测定了3种化学药剂及其分别与复配芽孢杆菌BEV2+FM2-4联合使用对马铃薯疮痂病的田间防效,结果表明,2.5%咯菌腈FS+BEV2+FM2-4的防效(72.57%)最好;3种化学药剂单用时,50%氟啶胺SC对马铃薯疮痂病的防治效果(66.50%)最好;BEV2+FM2-4对马铃薯疮痂病的防治效果为70.17%,明显优于对照药剂解淀粉芽孢杆菌QST713(56.77%)。本研究发现的菌药联合使用防治马铃薯疮痂病的方法,可为今后生产实践中马铃薯疮痂病的防治提供有效的技术支持。展开更多
OBJECTIVE:To further evaluate the complementary effect of Yiqi Huoxue Jiedu decoction(YHJD)on patients with advanced epithelial ovarian cancer(EOC).METHODS:All 330 enrolled participants diagnosed with stageⅢc EOC wer...OBJECTIVE:To further evaluate the complementary effect of Yiqi Huoxue Jiedu decoction(YHJD)on patients with advanced epithelial ovarian cancer(EOC).METHODS:All 330 enrolled participants diagnosed with stageⅢc EOC were randomly divided into two groups that received YHJD or a placebo.The primary end point was health-related quality of life(HRQL)measured by the functional assessment of cancer therapy-ovary cancer(FACT-O)questionnaire.The secondary end point was progression-free survival(PFS).RESULTS:A total of 299 participants completed the trial with 153 and 146 in YHJD and control groups,respectively.After 6 months of treatment,YHJD increased physical wellbeing(PWB),functional wellbeing(FWB),additional concerns(AC),and the trial outcome index(TOI)(P<0.05)by various degrees compared with the baseline.YHJD also had notable advantages over the placebo at 3 and 6 months in terms of PWB,FWB,AC(P<0.05),and TOI(P<0.01).In addition,YHJD had a significant advantage in terms of PFS compared with the placebo(21 vs18 months,P<0.05).No adverse events were reported.CONCLUSION:YHJD is an effective and safe choice as a complementary therapy to improve HRQL and prolong PFS of stageⅢc EOC patients.展开更多
文摘马铃薯疮痂病(potato common scab)是由链霉菌(Streptomyces spp.)引起的土传兼种传细菌性病害,给马铃薯产业带来巨大的经济损失。为了筛选出防治马铃薯疮痂病的菌药组合,本研究将5株芽孢杆菌复配,筛选出对3种疮痂链霉菌的最优拮抗菌株组合BEV2+FM2-4,并通过萝卜幼苗试验验证了其对普通疮痂链霉菌(S. scabies)SCA3有明显的拮抗作用。采用平板菌落计数法测定了3种化学药剂(2.5%咯菌腈悬浮种衣剂(FS)、50%氟啶胺悬浮剂(SC)和20%溴硝醇可溶液剂(SL))对疮痂链霉菌的抑制作用,结果表明,50%氟啶胺SC对疮痂链霉菌的抑制效果最好,其EC_(50)值为0.442μg/mL;其次是20%溴硝醇SL,EC_(50)值为0.536μg/mL;2.5%咯菌腈FS的EC_(50)值为2.916μg/mL。测定了3种化学药剂及其分别与复配芽孢杆菌BEV2+FM2-4联合使用对马铃薯疮痂病的田间防效,结果表明,2.5%咯菌腈FS+BEV2+FM2-4的防效(72.57%)最好;3种化学药剂单用时,50%氟啶胺SC对马铃薯疮痂病的防治效果(66.50%)最好;BEV2+FM2-4对马铃薯疮痂病的防治效果为70.17%,明显优于对照药剂解淀粉芽孢杆菌QST713(56.77%)。本研究发现的菌药联合使用防治马铃薯疮痂病的方法,可为今后生产实践中马铃薯疮痂病的防治提供有效的技术支持。
文摘基于Sentinel-2 NDVI(normalized difference vegetation index)时间序列数据特征绘制了江汉平原2020—2024年的农作物种植强度空间分布并分析其变化特征。首先对NDVI数据进行了云掩膜和时序平滑等预处理获取完整的作物NDVI时序曲线;然后,提取曲线的波峰和波谷、作物的SOS(start of season)和EOS(end of season)等关键物候信息,在此基础上提出了一种波峰计数的种植强度提取方法,并通过野外调查数据进行了精度验证。研究结果表明,该方法能够有效绘制江汉平原单季作物、双季轮作和三季轮作的空间分布,5 a整体精度均超过85%。该方法为精准农业的发展提供了可靠的技术手段。
基金Supported by National Natural Science Foundation of China(NSFC)-funded Project:the Mechanisms of Tailored Immunotherapy of Yiqi Huoxue Jiedu Decoction Modulating T Regulatory Cells at the Level of the Tumor Microenvironment and Inherited Single Nucleotide Polymorphisms in Advanced Ovarian Cancer(No.81473566).
文摘OBJECTIVE:To further evaluate the complementary effect of Yiqi Huoxue Jiedu decoction(YHJD)on patients with advanced epithelial ovarian cancer(EOC).METHODS:All 330 enrolled participants diagnosed with stageⅢc EOC were randomly divided into two groups that received YHJD or a placebo.The primary end point was health-related quality of life(HRQL)measured by the functional assessment of cancer therapy-ovary cancer(FACT-O)questionnaire.The secondary end point was progression-free survival(PFS).RESULTS:A total of 299 participants completed the trial with 153 and 146 in YHJD and control groups,respectively.After 6 months of treatment,YHJD increased physical wellbeing(PWB),functional wellbeing(FWB),additional concerns(AC),and the trial outcome index(TOI)(P<0.05)by various degrees compared with the baseline.YHJD also had notable advantages over the placebo at 3 and 6 months in terms of PWB,FWB,AC(P<0.05),and TOI(P<0.01).In addition,YHJD had a significant advantage in terms of PFS compared with the placebo(21 vs18 months,P<0.05).No adverse events were reported.CONCLUSION:YHJD is an effective and safe choice as a complementary therapy to improve HRQL and prolong PFS of stageⅢc EOC patients.
